Guy Sauvageau
M.D., Ph.D, FRCP(C)
Co-Chief Executive Officer
Internationally recognized stem cell biologist, co-identified UM171 and co-founded the Center for cell therapy of Montreal and the Quebec Leukemia Cell Bank.
Guy Sauvageau
M.D., Ph.D, FRCP(C)
Co-Chief Executive Officer
Internationally recognized stem cell biologist, co-identified UM171 and co-founded the Center for cell therapy of Montreal and the Quebec Leukemia Cell Bank.
David Millette
CA, CPA, CFA, Lawyer
Co-Chief Executive and Chief Operating Officer
Over 20 years of experience in business management and advisory services. Broad range of financial, legal and strategic experience across several industries, including pharmaceuticals, life sciences and healthcare.
Pierre Caudrelier
M.D.
Chief Medical Officer
Over 30 years of experience in various positions in the Pharma and Biotech sectors. He has published 21 articles and is inventor or co-inventor on 19 patents from 2 patent families.
Isabelle Martin
CPA, MBA
VP Finance
Over 20 years of experience in business management and finance. Broad range of complex business models through 15 years of experience as VP of Finance in major international manufacturing groups based in Europe and Canada, including Automotive, Paper, Plastics and Banking industries.
Jean Proulx
M.Sc., MBA
VP Medical and Scientific Affairs
25 years of experience in the pharmaceutical industry. Previously engaged in R&D, registration and commercialization of innovative treatments for cardiovascular, venous diseases and oncology at Servier.
Nathalie Bourgouin
M.Sc.
VP Quality and Compliance
Over 30 years of experience in quality and compliance in Pharmaceuticals and Biotech. She was VP Compliance at Skillpad and Senior Director Global Clinical and Regulatory Affairs Compliance at Aptalis. Her expertise is developing compliant risk-based quality assurance processes.
Michael May
Chairman of the Board, ExCellThera
President and CEO of the Centre for Commercialization of Regenerative Medicine (CCRM).
Elizabeth Douville
Director
President and CEO of IRICoR, a Center of Excellence in Commercialization and Research specializing in drug discovery in oncology and related areas, based at IRIC/University of Montreal.
Michael Hanley
Director
Corporate director with 25+ years of experience in senior management roles and corporate governance; Lead Director, Nuvei; Director, LyondellBasell
Guy Sauvageau
Co-Chief Executive Officer
Internationally recognized stem cell biologist, co-identified UM171 and co-founded the Center for cell therapy of Montreal and the Quebec Leukemia Cell Bank.
Richard Cherney
Director
Managing Partner at Davies Ward Phillips & Vineberg. 35+ years of experience as legal partner to Canadian public and private companies . Has served as a director of several public companies.
Anne Marinier
Co-Founder
25+ years of experience in medicinal chemistry . Co-founded and led IRIC’s Drug Discovery Unit, and identified UM171. Previously Group Leader in the Drug Discovery Research group at Bristol-Myers Squibb.
David Millette
CA, CPA, CFA, Lawyer
Co-Chief Executive and Chief Operating Officer
Over 20 years of experience in business management and advisory services. Broad range of financial, legal and strategic experience across several industries, including pharmaceuticals, life sciences and healthcare.
Peter Zandstra
Ph.D., FRSC(E)
Co-founded three biotech companies, including ExCellThera and Notch Therapeutics
Director and Professor at UBC’s Michael Smith Laboratories Internationally recognized cell engineering expert.
Steve Woodside
Ph.D.
Senior Director, Engineering at Notch Therapeutics
Previously held senior development positions at STEMCELL Technologies. 20+ years of experience in science and technology R&D.
Andromachi (Machi) Scaradavou
M.D.
Transplant Physician at Memorial Sloan-Kettering Cancer Center
Pediatric hematologist and oncologist with extensive experience in bone marrow transplants.
Keith Humphries
M.D., Ph.D., FRCP(C)
Part of the BC Cancer Agency for 30 years. Major research interests include Gene Therapy by targeting hematopoietic stem cells with special emphasis on hemoglobinopathies.
Bernhard Gentner
M.D.
Group leader, Translational Stem Cell and Leukaemia Unit at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget)
Group leader, Translational Stem Cell and Leukaemia Unit at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget)